[HTML][HTML] Novel agents for the pharmacological treatment of alcohol use disorder

EM Burnette, SJ Nieto, EN Grodin, LR Meredith… - Drugs, 2022‏ - Springer
Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with
only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous …

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease

M Thursz, A Gual, C Lackner, P Mathurin, C Moreno… - Journal of …, 2018‏ - Elsevier
The harmful use of alcohol has been estimated to cause approximately 3.3 million deaths
every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective …

Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial

EM Beraha, E Salemink, AE Goudriaan… - European …, 2016‏ - Elsevier
Previous randomised placebo-controlled trials with low-to-medium doses of baclofen (30–60
mg) showed inconsistent results, but case studies suggested a dose-response effect and …

Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes

K Mann, CR Roos, S Hoffmann, H Nakovics… - …, 2018‏ - nature.com
Randomized trials of medications for alcohol dependence (AD) often report no differences
between active medications. Few studies in AD have tested hypotheses regarding which …

Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study

W van den Brink, P Sørensen, L Torup… - Journal of …, 2014‏ - journals.sagepub.com
This study evaluated the long-term efficacy and safety of nalmefene treatment in reducing
alcohol consumption. We randomised (1: 3) 675 alcohol-dependent patients≥ 18 years of …

Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction …

B Rolland, F Paille, C Gillet, A Rigaud… - CNS Neuroscience …, 2016‏ - Wiley Online Library
Summary Background The latest French good practice recommendations (GPR s) for the
screening, prevention, and treatment of alcohol misuse were recently published in …

Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy

K Mann, L Torup, P Sørensen, A Gual, R Swift… - European …, 2016‏ - Elsevier
Nalmefene, a mu-and delta-opioid receptor (MOR, DOR) antagonist and a partial kappa-
opioid receptor (KOR) agonist, is approved in the European Union and other countries for …

Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double …

C Palpacuer, B Laviolle, R Boussageon… - PLoS …, 2015‏ - journals.plos.org
Background Nalmefene is a recent option in alcohol dependence treatment. Its approval
was controversial. We conducted a systematic review and meta-analysis of the aggregated …

[ספר][B] The myth of the moral brain: The limits of moral enhancement

H Wiseman - 2016‏ - books.google.com
An argument that moral functioning is immeasurably complex, mediated by biology but not
determined by it. Throughout history, humanity has been seen as being in need of …

Pharmacotherapy of alcoholism–an update on approved and off-label medications

M Soyka, CA Müller - Expert opinion on pharmacotherapy, 2017‏ - Taylor & Francis
Introduction: Only a few medications are available for the treatment of alcohol use disorders
(AUDs). Areas covered: This paper discusses approved AUD medications, including the …